RxDoctor Payments Data

Deborah Combs-Cantrell, MD

Neurology · Lewisville, TXNPI 1326144304

Payments from drug & device makers

$134,810in general payments, 2019–2025

Across 1,503 payments — averaging $89.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$45K
  • SK Life Science, Inc.$26K
  • UCB, Inc.$24K
  • Eisai Inc.$10K
  • Biohaven Pharmaceutical Holding Company Ltd.$6K
  • Supernus Pharmaceuticals, Inc.$4K
  • plus $20K from 44 others

What the payments were for

  • Consulting fees$3,2202%
  • Speaking & faculty fees$104,27077%
  • Travel & lodging$1,6321%
  • Food & beverage$25,56219%
  • Education$1260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$134,810 in reported general payments places this provider in the 85th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$777,797
Medicare patients
275
Services billed
12,243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KeppraLevetiracetam78$178,406
BriviactBrivaracetam53$168,806
FycompaPerampanel66$110,629
ZeposiaOzanimod Hydrochloride12$107,550
XcopriCenobamate76$101,260
VimpatLacosamide46$79,257
LamictalLamotrigine73$77,754
Trokendi XrTopiramate39$58,177
AptiomEslicarbazepine Acetate23$40,710
RexultiBrexpiprazole19$39,457
QuliptaAtogepant18$37,985
FelbatolFelbamate12$37,042
NayzilamMidazolam16$35,116
Keppra XrLevetiracetam11$27,308
Emgality PenGalcanezumab-Gnlm22$23,024

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact, Vimpat, Nayzilam$23,892$283,178115 claims
Eisai Inc.Fycompa$10,368$110,62966 claims
SK Life Science, Inc.Xcopri$25,753$101,26076 claims
Supernus Pharmaceuticals, Inc.Trokendi Xr$4,463$58,17739 claims
Sunovion Pharmaceuticals Inc.Aptiom$495$40,71023 claims
Otsuka America Pharmaceutical, Inc.Rexulti$57$39,45719 claims
AbbVieQulipta$44,880$37,98518 claims
Lundbeck LLCOnfi$779$9,64511 claims
PfizerDilantin$4,178$6,99031 claims
Upsher-smith Laboratories LLCTopiramate$60$2,053129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,246 neurology providers in Texas.

Other neurology in Lewisville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →